Buy Levofloxacin pills 500 mg 5 pcs
  • Buy Levofloxacin pills 500 mg 5 pcs


1421 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

It has a protective effect on the normal intestinal microflora, thereby has increased gastrointestinal safety. Along with a powerful broad spectrum antibacterial effect, it has an immunomodulatory effect, which can be especially important in the treatment of chronic or recurrent diseases of infectious etiology.


Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

  • lower respiratory tract (exacerbation of chronic bronchitis, community-acquired pneumonia);
  • ENT organs (including acute sinusitis);
  • urinary tract and kidneys (including acute pyelonephritis);
  • skin and soft tissue (abscesses, furunculosis);
  • chronic bacterial prostatitis;
  • intra-abdominal infections;
  • drug-resistant forms of tuberculosis - as part of complex therapy.


One tablet contains:
Active ingredient: levofloxacin hemihydrate (in terms of levofloxacin) 500 mg;
Excipients: lactulose, lactose monohydrate, low molecular weight povidone, croscarmellose sodium, sodium lauryl sulfate, talc, magnesium stearate, microcrystalline cellulose;
Shell auxiliary substances: hypromellose, talc, titanium dioxide, macrogol-4000.

Levofloxacin is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Levofloxacin AVVA RUS Russia pills
Levostar Actavis Ltd Iceland pills
Levofloxacin Vertex Russia pills
Floracid Valenta Russia pills
L-Optic® Rompharm K.O.Romparm Company S.R.L Romania eye drops
Signatum Sentiss Pharma India eye drops
Oftakviks Santen France eye drops

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Orally, before a meal or in a break between meals, without chewing, drinking a sufficient amount of liquid.
Acute sinusitis: 500 mg 1 time per day for 10-14 days;
Community-acquired pneumonia: 500 mg 1-2 times a day, 7-14 days;
Exacerbation of chronic bronchitis: 250-500 mg 1 time per day for 7-10 days;
Uncomplicated urinary tract infections - 250 mg 1 time per day for 3 days;
Complicated urinary tract infections (including pyelonephritis): 250 mg 1 time per day (for severe disease, the dose should be increased) for 7-10 days;
Chronic bacterial prostatitis - 500 mg 1 time per day, the course of treatment - 28 days;
Infections of the skin and soft tissues: 250-500 mg 1-2 times a day for 7-14 days;
Intraabdominal infection - 500 mg 1 time per day, treatment 7-14 days (in combination with antibacterial drugs acting on anaerobic microflora);
Combined therapy of drug-resistant forms of tuberculosis: 500 mg 1-2 times a day, the course of treatment is up to 3 months;
The duration of treatment depends on the type and severity of the disease.
After stopping the symptoms of acute inflammation and normalizing the temperature, it is recommended to continue therapy with levofloxacin for 48-72 hours.

Dosing of the drug in patients with impaired renal function (creatinine clearance less than 50 ml / min):

    • 50-20 ml / min:
      Initial dose of 250 mg / 24 h: further 125 mg / 24 h;
      Initial dose of 500 mg / 24 h: further 250 mg / 24 h;
      Initial dose of 500 mg / 12 h: further 250 mg / 12 h;
    • 19-10 ml / min:
      Initial dose of 250 mg / 24 h: further 125 mg / 48 h;
      Initial dose of 500 mg / 24 h: further 125 mg / 24 h;
      Initial dose of 500 mg / 12 h: further 125 mg / 12 h;
  • ? 10 * ml / min:
    Initial dose of 250 mg / 24 h: further 125 mg / 48 h;
    Initial dose of 500 mg / 24 h: further 125 mg / 24 h;
    Initial dose of 500 mg / 12 h: further 125 mg / 24 h;

* including with hemodialysis and continuous ambulatory peritoneal dialysis

After hemodialysis or permanent ambulatory peritoneal dialysis, no additional doses are required.
Dose adjustment is not required in patients with impaired liver function.

Adverse reactions

On the part of the digestive system: nausea, vomiting, diarrhea (including blood), indigestion, loss of appetite, abdominal pain, pseudomembranous colitis; increased activity of liver enzymes, hyperbilirubinemia, hepatitis, dysbacteriosis.
Since the cardiovascular system: lower blood pressure, vascular collapse, tachycardia, prolongation of the QT interval, atrial fibrillation.
Nervous system disorders: headache, dizziness, weakness, drowsiness, insomnia, tremor, anxiety, paresthesias, fear, hallucinations, confusion, depression, movement disorders, convulsions.
From the senses: visual impairment, hearing, smell, taste and tactile sensitivity.
On the part of the musculoskeletal system: arthralgia, muscular weakness, myalgia, tendon rupture, tendonitis, rhabdomyolysis.
From the urinary system: hypercreatininemia, interstitial nephritis, acute renal failure.
From the side of blood-forming organs: eosinophilia, hemolytic anemia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemorrhages.
Metabolism: hypoglycemia (increased appetite, increased sweating, tremors).
Allergic reactions include itching and redness of the skin, swelling of the skin and mucous membranes, urticaria, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospasm, asthma, anaphylactic shock, allergic pneumonitis, vasculitis.
Other: asthenia, exacerbation of porphyria, photosensitization, persistent fever, development of superinfection.


Hypersensitivity to levofloxacin, other fluoroquinolones or components of the drug, epilepsy, tendon damage during previous treatment with quinolones, pregnancy, lactation, childhood and adolescence (under 18)
Lactose intolerance or lactase deficiency, as well as glucose-galactose malabsorption.
With care for the elderly, with a deficiency of glucose-6-phosphate dehydrogenase.

Drug interactions

There are reports of a pronounced decrease in the convulsive readiness threshold with simultaneous use of quinolones and substances that lower the cerebral threshold of convulsive readiness. This also applies to the simultaneous administration of quinolones and theophylline, as well as non-steroidal anti-inflammatory drugs - propionic acid derivatives.
The effect of the drug is weakened when applied simultaneously with sucralfate, antacids containing magnesium or aluminum, and iron salts. Levofloxacin should be taken no less than 2 hours before taking these medicines.
With the simultaneous use of vitamin K antagonists, monitoring of blood coagulation parameters is necessary.
Renal clearance of levofloxacin is slightly slowed down by cimetidine and probenecid. Levofloxacin slightly increases the half-life of cyclosporine.
Taking glucocorticosteroids increases the risk of tendon rupture.

Special instructions

In the treatment of elderly patients should be borne in mind that they often suffer from impaired renal function.
Despite the fact that photosensitivity during treatment with levofloxacin is rarely observed, patients are not recommended to undergo strong solar or artificial ultraviolet radiation.
If pseudomembranous colitis is suspected, you should immediately cancel levofloxacin and begin appropriate treatment. In such cases, you can not use drugs that inhibit intestinal motility.
Patients with glucose-6-phosphate dehydrogenase deficiency (a hereditary metabolic disorder) can respond to fluoroquinolones by destroying red blood cells (hemolysis). In this regard, treatment with levofloxacin should be carried out with caution.
Side effects of levofloxacin, such as dizziness or drowsiness, as well as visual impairment (see the “Side Effects” section), can impair reactivity and hamper driving and maintaining machinery.


Symptoms of a drug overdose of levofloxacin appear at the level of the central nervous system (confusion, dizziness, impaired consciousness and convulsions). In addition, gastrointestinal disorders (eg, nausea, vomiting) and erosive lesions of the mucous membranes of the gastrointestinal tract may occur. In studies conducted with ultra-high doses of levofloxacin, prolongation of the QT interval has been shown.
Levofloxacin is not eliminated by hemodialysis or peritoneal dialysis. There is no specific antidote (opposing agent).
Treatment - gastric lavage and symptomatic therapy.

  • Brand name: Levofloxacin
  • Active ingredient: Levofloxacin
  • Dosage form: Film Coated pills
  • Manufacturer: AVVA RUS
  • Country of Origin: Russia

Studies and clinical trials of Levofloxacin (Click to expand)

  1. Recognition properties of poly(vinylidene fluoride) hollow-fiber membranes modified by levofloxacin-imprinted polymers
  2. Poly-D, L-lactide and levofloxacin-blended beads: A sustained local releasing system to treat osteomyelitis
  3. Synthesis and Antibacterial Activity of Nitroaryl Thiadiazole-Levofloxacin Hybrids
  4. Temperature-dependent specific transport of levofloxacin in human intestinal epithelial LS180 cells
  5. Gold nanoparticles-based fluorescence enhancement of the terbium–levofloxacin system and its application in pharmaceutical preparations
  6. Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study
  7. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies
  8. Photophysical and Phototoxic Properties of the Antibacterial Fluoroquinolones Levofloxacin and Moxifloxacin
  9. ChemInform Abstract: An Improved Synthesis of Levofloxacin.
  10. ChemInform Abstract: Synthesis of a Key Intermediate of Levofloxacin via Enantioselective Hydrogenation Catalyzed by Iridium(I) Complexes.
  11. ChemInform Abstract: Enantioselective Synthesis of Key Intermediate (II) of Levofloxacin Using Microbial Resolution.
  12. ChemInform Abstract: An Efficient Synthesis of Ofloxacin and Levofloxacin from 3,4-Difluoroaniline.
  13. ChemInform Abstract: Peptidomimetics of Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa.
  14. Synthesis and Biological Testing of Non-Fluorinated Analogues of Levofloxacin.
  15. Synthesis and Antibacterial Activity of Nitroaryl Thiadiazole-Levofloxacin Hybrids.
  16. Synthesis and Antibacterial Activity of Levofloxacin Derivatives with Certain Bulky Residues on Piperazine Ring.
  17. ChemInform Abstract: Enantiopure 1,4-Benzoxazines via 1,2-Cyclic Sulfamidates. Synthesis of Levofloxacin.
  18. ChemInform Abstract: A Convenient Synthesis of Chiral Amino Acid Derived 3,4-Dihydro-2H-benzo[b][1,4]thiazines and Antibiotic Levofloxacin.
  19. ChemInform Abstract: Synthesis, Characterization and Biological Evaluation of a Series of Levofloxacin Carboxamide Analogues.
  20. Determination of levofloxacin and norfloxacin by capillary electrophoresis with electrochemiluminescence detection and applications in human urine
  21. Technetium-99m labeling and freeze-dried kit formulation of levofloxacin (L-Flox): a novel agent for detecting sites of infection
  22. Synthesis of [11C]levofloxacin
  23. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro
  24. Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin

Customers who bought this product also bought:

8 other products in the same category: